Pharmesis International Ltd.

Equities

BFK

SG1BH6000003

Pharmaceuticals

Market Closed - Singapore S.E. 04:37:49 2024-04-26 am EDT 5-day change 1st Jan Change
0.12 SGD +50.00% Intraday chart for Pharmesis International Ltd. +50.00% +22.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pharmesis’ Attributable Loss for 2023 Widens MT
Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director CI
Pharmesis Launches New Product Line MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months and Full Year Ended 31 December 2023 CI
Pharmesis International Ltd. Announces Changes to the Composition of the Board and Board Committees CI
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pharmesis International Flags Losses for H1 MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023 CI
Pharmesis International Ltd. Announces Management Resignations CI
Pharmesis International Ltd. Appoints Lin Yimin as Non-Independent Non-Executive Director and A Member of Audit Committee CI
Pharmesis International Ltd. Announces Temporary Work Stoppages at its Manufacturing Facilities Located in Gulin County, Luzhou City, Sichuan Province CI
Pharmesis International Issues 4.6 Million Shares to Two Subscribers MT
Pharmesis International Gets Regulatory Nod to List 4.6 Million Shares MT
Pharmesis International to Issue 4.6 Million Shares to Two Subscribers MT
Pharmesis International Expects Loss in H2, FY22 MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Pharmesis International's Attributable Loss Widens in H1 MT
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Pharmesis International to Post Losses in H1 Amid Lower Sales MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2022 CI
Pharmesis International Ltd. Appoints Cheok Hui Yee as Company Secretary CI
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Pharmesis International to Swing Back to Profit in FY21 MT
Pharmesis International Ltd. Provides Earnings Guidance for the Second Half and Financial Year Ended 31 December 2021 CI
Chart Pharmesis International Ltd.
More charts
Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
More about the company
  1. Stock Market
  2. Equities
  3. BFK Stock
  4. News Pharmesis International Ltd.
  5. Pharmesis International Issues 4.6 Million Shares to Two Subscribers